Author Manuscript Published OnlineFirst on September 14, 2011; DOI: 10.1158/1078-0432.CCR-11-1157 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A novel kinase inhibitor INCB28060 blocks c-MET-dependent signaling, neoplastic activities, and crosstalk with EGFR and HER-3 Xiangdong Liu*, Qian Wang, Gengjie Yang, Cindy Marando, Holly K. Koblish, Leslie M Hall, Jordan S. Fridman, Elham Behshad, Richard Wynn, Yu Li, Jason Boer, Sharon Diamond, Chunhong He, Meizhong Xu, Jincong Zhuo, Wenqing Yao, Robert C. Newton, Peggy A. Scherle. Incyte Corporation, Wilmington, DE 19880 Running Title: INCB28060, a c-MET kinase selective inhibitor Keywords: Hepatocyte growth factor (HGF), c-MET receptor tryrosine kinase, kinase inhibitor, epithelial growth factor receptor (EGFR), and cancer *Corresponding Author: Incyte Corporation, Route 141 and Henry Clay Road, Building E400/3229C, Wilmington, DE 19880. Phone: 302-498-6815; Fax: 302-425-2760; E-mail:
[email protected]. Competing Interests: All authors are employees of and/or own stock in Incyte Corporation. Word count: 5257 Total number of figures and tables: (6 figures and 2 tables) 1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 14, 2011; DOI: 10.1158/1078-0432.CCR-11-1157 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. TRANSLATIONAL RELEVANCE The c-MET pathway plays important roles in human cancer and presents an attractive therapeutic target. This study describes preclinical characterization of INCB28060, a selective and potent c-MET kinase inhibitor currently being studied in patients.